

**Matveev Vsevolod - President, Russian Association of Oncologic Urology.
Scientific Director of N.N.Blokhin National Cancer Research Center, Moscow**

Educational Background

Moscow Sechenov Medical Academy, Moscow, Russia, 1984 – 1990

Qualification: MD, Diploma ФВ #012387 issued on 24 – Jun – 1990

POSTGRADUATE QUALIFICATIONS:

17.05.94. Candidate of Medicine

30.06.94. Urology Researcher

22.04.97 Sponsored trainee of Royal College of Surgeons of England

26.04.2002 Doctor of Medicine

02.02.2007 Professor of Oncology, 2007

28.10.2016 respondent member of Russian Academy of Sciences

POSTGRADUATE OR FURTHER TRAINING

Advanced course in oncology, Russian Medical Academy of Post-graduate Education within the Ministry of Healthcare of the Russian Federation, Moscow, Russia, 2004, 2009, 2014.

Advanced course in urology, Russian Medical Academy of Post-graduate Education within the Ministry of Healthcare of the Russian Federation, Moscow, Russia, 2000, 2006, 2011, 2016.

Course: Salzburg Oncology Seminar, October 2000, Salzburg, Austria

Observer at Urological Clinic University of Jena, Germany, October 1999

Fellowship of Royal College of Surgeons of England, Royal Free Hospital, London UK, 1995-1997

Visiting resident at department of Urology, Royal Free Hospital, London, UK. Oct-Dec 1993.

PhD, Research Fellowship, Research Institute of Urology under the Ministry of Healthcare of the Russian Federation, Moscow, Russia, 1991 – 1994 (Diploma КН # 007302, issued 08 Jul 1994)

PREVIOUS APPOINTMENTS

Head department of Urology N.N.Blokhin Cancer Research Center, 2005-2017

Associate Professor, Department of Urology, N.N.Blokhin Cancer Research Center, under the Russian Academy of Medical Science, Moscow, Russia, 1999 – 2005

Research Associate, Department of Surgical Oncurology, Blokhin Cancer Research Center, under the Russian Academy of Medical Science, Moscow, Russia, 1997 – 1999

Senior House Officer, Royal Free Hospital, London, UK, 1995 – 1997

Surgeon, Department of Surgical Oncurology, Blokhin Cancer Research Center, under the Russian Academy of Medical Science, Moscow, Russia, 1994 – 1995

Resident in Urology, N.N.Lopatkin Research Institute of Urology under the Ministry of Healthcare of the Russian Federation, Moscow, Russia, 1990 – 1994,

Surgeon (part time) 1990 – 1992 Moscow Emergency Hospital N7

MEMBERSHIPS

Vice-chairman of Russian Association of Urology

Member of Russian Association of Endourology

President of Russian Association of Oncological Urology

Member of EAU prostate cancer guideline group (2006-2017)

Member of European Association of Urology

Member of EORTC GU group

CLINICAL RESEARCH EXPERIENCE

Trial name	type of cancer	phase	title	year
MO29983	urothelial cancer	III	PI	2017 ongoing
WO30070	urothelial cancer	III	PI	2017 ongoing.
MK3475-427-00	RCC	II	PI	2017 ongoing.
MK3475-426-00	RCC	III	PI	2017 ongoing.

MK3475-057-00	urothelial cancer	II	PI	2016	2017
D419BC00001	urothelial cancer	III	PI	2016	ongoing.
JNJ-56021927					
PCR3003 ATLAS	prostate cancer	III	PI	2016	ongoing.
JNJ-56021927					
PCR3002 TITAN	prostate cancer	III	PI	2016	ongoing.
JNJ-42756493					
BLC2001	urothelial cancer	II	PI	2016	ongoing.
JNJ-56021927					
PCR3001	prostate cancer	III	PI	2016	2017.
BAY 88-8223/15396	prostate cancer	III	PI	2015	2017.
BAY 88-8223/16216	prostate cancer	II	PI	2015	2016
D081DC00008	prostate cancer	II	PI	2015	2017.
AB12003	prostate cancer	III	PI	2015	2017.
9785-MA-1001	prostate cancer	III	PI	2015	2017.
9785-CL-0122	prostate cancer	II	PI	2014	2017.
A-38-52014-194	prostate cancer	III	PI	2014	2017
MDV3100-14	prostate cancer	III	PI	2014	2017.
2010-01(Magnolia)	urothelial cancer	II	PI	2014	2016
MIP-1404-201	prostate cancer	II	PI	2013	2014
OGX-011-12	prostate cancer	III	PI	2013	2016
CA209025	RCC	III	PI	2013	2016
212082PCR3011	prostate cancer	III	PI	2013	2016
ABI-PRO-3002	prostate cancer	III	PI	2012	2016
VEG 113387	RCC	III	PI	2011	2016
MDV 3100-03	prostate cancer	III	PI	2011	2015

EFC 11785		III	PI		2011	2016
212082PCR3001	prostate cancer	II	PI		2011	2015
IMA 901-301	RCC	III	PI		2011	2015
20080560	prostate cancer	III	PI		2010	2013
CA 184-043	prostate cancer	III	PI		2009	2013
AV-951-09-301	prostate cancer	III	PI		2009	2013
CRAD001L2201	RCC	II	PI		2009	2013
EFC6668	urothelial cancer	III	PI		2009	2010
CA180227 2014	prostate cancer		III	PI		2009
MO21609 2012	RCC	II	PI			2009
EFC6 546 (VENICE)	prostate cancer		III	PI	2009	2012
306 K1-3311-WW	RCC	III	PI		2009	2015
D432 0C00015	prostate cancer		III	PI	2008	2011
ARI109924	prostate cancer		II	PI	2008	2011
06762004	RCC	II/III	PI		2007	2014
AT-101-CS-205	prostate cancer		II	PI	2007	2010
WX-2003-07HR	RCC	III	PI		2006	2013
EGD-EC-003	prostate cancer		III	PI	2006	2013
TV3/001/06	RCC	III	PI		2006	2009
XRP6976J/3501	prostate cancer		III	PI	2006	2007
IROF-018 2006	prostate cancer		II	CI		2005
GPC SAT3-03-01 2006	prostate cancer		III	CI		2004
BO18039	prostate cancer	III	CI		2004	2006

MI-CP098 2006	prostate cancer	II	CI		2004
3066K1-304-WW	RCC	III	CI	2004	2005
RP 56976V-327	prostate cancer	III	CI	2000	2002
-	prostate cancer	II	CI	1998	2000

Important recent publications

1. [A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia.](#) Ye D, Huang Y, Zhou F, Xie K, **Matveev V**, et al. Asian J Urol. 2017 Apr;4(2):75-85. doi: 10.1016/j.ajur.2017.01.002. Epub 2017
2. [Custirsen \(OGX-011\) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel \(AFFINITY\): a randomised, open-label, international, phase 3 trial.](#) Beer TM, Hotte SJ, Saad F, Alekseev B, **Matveev V**, Fléchon A, Gravis et.al. Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.
3. [Re: Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.](#) **Matveev VB**, Volkova MI. Eur Urol. 2017 Dec;72(6):1024. doi: 10.1016/j.eururo.2017.08.029. Epub 2017
4. [Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.](#)

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators.
N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4.

5. [What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.](#)

Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, **Matveev VB**, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O.
Eur Urol. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. 2017 Mar 21.

6. [The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.](#)

Fossati N, Willemse PM, Van den Broeck T, van den Bergh RCN, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S.
Eur Urol. 2017 Jul;72(1):84-109. doi: 10.1016/j.eururo.2016.12.003. Epub 2017 Jan 24.
Review.

7. [EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.](#)

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, **Matveev VB**, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.
Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug.

8. [Loss of Cell Differentiation in HPV-Associated Bladder Cancer.](#)

Golovina DA, Ermilova VD, Zavalishina LE, Andreeva YY, **Matveev VB**, Frank GA, Volgareva GM. Bull Exp Biol Med. 2016 May;161(1):96-8. doi: 10.1007/s10517-016-3354-x. Epub 2016 Jun 6.

9. [Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.](#)

van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, **Matveev V**, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N.

Eur Urol. 2016 May;69(5):802-20. doi: 10.1016/j.eururo.2015.11.023. Epub 2015 Dec 12. Review.

10. [Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study \(ICELAND\).](#)

Schulman C, Cornel E, **Matveev V**, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, Gómez Veiga F, Baskin-Bey E, López B, Tombal B. Eur Urol. 2016 Apr;69(4):720-7.

11. [Protein kinase A type II- \$\alpha\$ regulatory subunit regulates the response of prostate cancer cells to taxane treatment.](#)

Zynda ER, **Matveev V**, Makhanov M, Chenchik A, Kandel ES. Cell Cycle. 2014;13(20):3292-301.

12. [Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.](#)

van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, **Matveev V**, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N. Eur Urol. 2015 Dec 12.

13. [Reduced morbidity in resection of residual tumors after chemotherapy for seminoma.](#)

Pfister D, Porres D, **Matveev V**, Heidenreich A. Urologe A. 2015 Oct;54(10):1402-6. doi: 10.1007/s00120-014-3708-9. German.

14. [Complex of molecular genetic and immunohistochemical methods for detection of human papillomavirus in the bladder cancer epithelium.](#)

Golovina DA, Trofimova OB, Ermilova VD, **Matveev VB**, Volgareva GM. Bull Exp Biol Med. 2014 May;157(1):70-3.

15. [Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer\(READY\): a randomised, double-blind phase 3 trial.](#)

Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, **Matveev VB**, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Lancet Oncol. 2013 Dec;14(13):1307-16.

16. [EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013](#). Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, **Matveev V**, Wiegel T, Zattoni F, Mottet N; European Association of Urology. Eur Urol. 2014 Jan;65(1):124-37.

17. [EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer](#). Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, **Matveev V**, Wiegel T, Zattoni F, Mottet N; European Association of Urology. Eur Urol. 2014 Feb;65(2):467-79. Review.

18. [A multinational phase II trial of bevacizumab with low-dose interferon- \$\alpha\$ 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN](#). Melichar B, Bracarda S, **Matveev V**, Alekseev B, Ivanov S, Zyryanov A, Janciauskiene R, Fernebro E, Mulders P, Osborne S, Jethwa S, Mickisch G, Gore M, van Moorselaar RJ, Staehler M, Magne N, Bellmunt J; BEVLiN Investigators. Ann Oncol. 2013 Sep;24(9):2396-402..

19. [Prostate cancer detection using mass-spectrometric profiling of low-molecular weight blood proteome]. Shevchenko VE, Cherniaev VA, Arnotskaia NE, **Matveev VB**. [Urologiia](#). 2013 Mar-Apr;(2):60-5..

20. Alteration of VHL gene in patients with metastatic renal cell carcinoma
Peters MV, **Matveev VB**, Volkova MI, Kalinin SA, Mikhaïlenko DM. [Urologiia](#). 2012 May-Jun;(3):22-7.

21. [\[Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer\]](#). Mikhaïlenko DS, Grigor'eva MV, Rusakov IG, Kuryinin RV, Popov AM, Peters MV, **Matveev VB**, Iakovlev ES, Nosov DA, Liubchenko LN, Tiuliandin SA, Strel'nikov VV, Zaletaev DV. [Mol Biol \(Mosk\)](#) 2012 Jan-Feb;46(1):71-81. Russian.

22. [The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma](#). Han SS, Yeager M, Moore LE, Wei MH, Pfeiffer R, Toure O, Purdue MP, Johansson M, Scelo G, Chung CC, Gaborieau V, Zaridze D, Schwartz K, Szeszenia-Dabrowska N, Davis F, Bencko V, Colt JS, Janout V, **Matveev V**, Foretova L et al. Hum Mol Genet. 2012 Mar 1;21(5):1190-200.

23. [Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.](#)

Sonpavde G, **Matveev V**, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Hood BA, Brookes M, Leopold L.

Ann Oncol. 2011 Nov 29. [Epub ahead of print]

24. [LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer.](#)

Liao LM, Brennan P, van Bemmelen DM, Zaridze D, **Matveev V**, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Rothman N, Boffetta P, Chow WH, Moore LE.

PLoS One. 2011;6(11):e27361. Epub 2011 Nov 4.

25. [Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells.](#)

Makhov PB, Golovine KV, Kutikov A, Canter DJ, Rybko VA, Roshchin DA, **Matveev VB**, Uzzo RG, Kolenko VM.

Carcinogenesis. 2011 Dec;32(12):1773-81. Epub 2011 Sep 22.

26. [Paclitaxel+BEP \(T-BEP\) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.](#)

Tryakin A, Fedyanin M, Kanagavel D, Fainstein I, Sergeev J, Polockij B, **Matveev V**, Zakharova T, Garin A, Tjulandin S

Urology. 2011 Sep;78(3):620-5. Epub 2011 Jul 20.

27. [Occupational exposure to dusts and risk of renal cell carcinoma.](#)

Karami S, Boffetta P, Stewart PS, Brennan P, Zaridze D, **Matveev V**, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Gromiec J, Slamova A, Chow WH, Rothman N, Moore LE.

Br J Cancer. 2011 May 24;104(11):1797-803. Epub 2011 May 3.

28. [EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.](#)

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, **Matveev V**, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. Eur Urol. 2011 Apr;59(4):572-83.

29. [A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.](#)

Van Poppel H, Da Pozzo L, Albrecht W, **Matveev V**, Bono A, Borkowski A, Colombel M, Klotz L, Skinner E, Keane T, Marreaud S, Collette S, Sylvester R.

Eur Urol. 2011 Apr;59(4):543-52. Epub 2010 Dec 22.

30. [Cellular expression of INK4a gene in cells of bladder cancer associated with human papilloma virus-16.](#) Volgareva GM, Zavalishina LE, Golovina DA, Andreeva YY, Ermilova VD, Trofimova OB, Kuevda DA, Shipulina OY, Glazunova VA, Cheng S, Pavlova LS, Cheban NL, **Matveev VB**, Frank GA.

Bull Exp Biol Med. 2010 Aug;149(2):242-5. English, Russian.

31. [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers].

Matveev VB, Volkova MI, Cherniev VA, Figurin KM, Mitin AV.

Urologiia. 2010 May-Jun;(3):41-7. Russian.

32. [Can lactase persistence genotype be used to reassess the relationship between renal cell carcinoma and milk drinking? Potentials and problems in the application of Mendelian randomization.](#)

Timpson NJ, Brennan P, Gaborieau V, Moore L, Zaridze D, **Matveev V**, Szeszenia-Dabrowska N, Lissowska J, Mates D, Bencko V, Foretova L, Janout V, Chow WH, Rothman N, Boffetta P, Harbord RM, Smith GD.

Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1341-8.

33. [Vitamin d pathway genes, diet, and risk of renal cell carcinoma.](#)

Karami S, Brennan P, Navratilova M, Mates D, Zaridze D, Janout V, Kollarova H, Bencko V, **Matveev V**, Szeszenia-Dabrowska N, Holcatova I, Yeager M, Chanock S, Rothman N, Boffetta P, Chow WH, Moore LE

Int J Endocrinol. 2010;2010:879362. Epub 2009 Nov 5.

34. [TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe.](#) Szymańska K, Moore LE, Rothman N, Chow WH, Waldman F, Jaeger E, Waterboer T, Foretova L, Navratilova M,

Janout V, Kollarova H, Zaridze D, **Matveev V**, Mates D, Szeszenia-Dabrowska N, Holcatova I, Bencko V, Villar S, Pawlita M, Boffetta P, Hainaut P, Brennan P.
Cancer Lett. 2010 Jul 1;293(1):92-8. Epub 2010 Feb 6.

35. [[Results of surgical and radiotherapy of prostatic cancer T1-4N0-1M0](#)].

Matveev VB, Tkachev SI, Volkova MI, Mitin AA, Kalinin SA, Shelepova VM. *Urologiia*. 2009 May-Jun;(3):33-9. Russian.

36. [An analysis of growth, differentiation and apoptosis genes with risk of renal cancer](#). Dong LM, Brennan P, Karami S, Hung RJ, Menashe I, Berndt SI, Yeager M, Chanock S, Zaridze D, **Matveev V**, Janout V, Kollarova H, Bencko V, Schwartz K, Davis F, Navratilova M, Szeszenia-Dabrowska N, Mates D, Colt JS, Holcatova I, Boffetta P, Rothman N, Chow WH, Rosenberg PS, Moore LE.

PLoS One. 2009 Mar 24;4(3):e4895.

37. [[Prognostic implications of preoperative diagnosis of clinically local and locally advanced prostatic cancer](#)].

Matveev VB, Volkova MI, Mitin AA, Kalinin SA, Ermilova VD.
Urologiia. 2009 Mar-Apr;(2):37-41. Russian.

38. [Tobacco smoking, body mass index, hypertension, and kidney cancer risk in central and eastern Europe](#).

Brennan P, van der Hel O, Moore LE, Zaridze D, **Matveev V**, Holcatova I, Janout V, Kollarova H, Foretova L, Szeszenia-Dabrowska N, Mates et al.
Br J Cancer. 2008 Dec 2;99(11):1912-5. Epub 2008 Oct 28

39. [[Study of alpha1-antichymotrypsin \(ACT\) in prostatic carcinoma](#)].

Karseladze AI, Rytin IE, Matveev VB.
Arkh Patol. 2005 Jan-Feb;67(1):30-3. Russian.

39. Granulocyte-Macrophage Colony-Stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-Risk Renal Cell Carcinoma. Ilya Tsimafeyeu, Lev Demidov, **Vsevolod Matveev**, Galina Kharkevich, Natalia Petenko
Journal of Cancer Science & Therapy. – 2010:2 (6), 157-159.

40. Detection of prostate cancer by plasma proteome profiling based on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

V.Chernyaev,V.E.Shevchenko,N.E.Arnotskaya,V.B.Matveev.
EJC 2011, 47, Suppl 4, pp33.